RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Seth Y. Ablordeppey to Humans

This is a "connection" page, showing publications Seth Y. Ablordeppey has written about Humans.
Connection Strength

0.346
  1. Ofori E, Onyameh EK, Gonela UM, Voshavar C, Bricker B, Swanson TL, Eshleman AJ, Schmachtenberg JL, Bloom SH, Janowsky AJ, Ablordeppey SY. New dual 5-HT1A and 5-HT7 receptor ligands derived from SYA16263. Eur J Med Chem. 2021 Mar 15; 214:113243.
    View in: PubMed
    Score: 0.036
  2. Asong G, Zhu XY, Bricker B, Andey T, Amissah F, Lamango N, Ablordeppey SY. New analogs of SYA013 as sigma-2 ligands with anticancer activity. Bioorg Med Chem. 2019 06 15; 27(12):2629-2636.
    View in: PubMed
    Score: 0.032
  3. Al-Ghanim L, Zhu XY, Asong G, Ablordeppey SY. SYA 013 analogs as moderately selective sigma-2 (s2) ligands: Structure-affinity relationship studies. Bioorg Med Chem. 2019 06 15; 27(12):2421-2426.
    View in: PubMed
    Score: 0.031
  4. Ofori E, Zhu XY, Etukala JR, Bricker BA, Ablordeppey SY. Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors. Bioorg Med Chem. 2016 11 15; 24(22):5730-5740.
    View in: PubMed
    Score: 0.027
  5. Etukala JR, Zhu XY, Eyunni SV, Onyameh EK, Ofori E, Bricker BA, Kang HJ, Huang XP, Roth BL, Ablordeppey SY. Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores. Bioorg Med Chem. 2016 08 15; 24(16):3671-9.
    View in: PubMed
    Score: 0.026
  6. Mazu TK, Bricker BA, Flores-Rozas H, Ablordeppey SY. The Mechanistic Targets of Antifungal Agents: An Overview. Mini Rev Med Chem. 2016; 16(7):555-78.
    View in: PubMed
    Score: 0.025
  7. Sampson D, Zhu XY, Eyunni SV, Etukala JR, Ofori E, Bricker B, Lamango NS, Setola V, Roth BL, Ablordeppey SY. Identification of a new selective dopamine D4 receptor ligand. Bioorg Med Chem. 2014 Jun 15; 22(12):3105-14.
    View in: PubMed
    Score: 0.023
  8. Sikazwe D, Grillo A, Ramsinghani S, Davis J, McQuiston K, Ablordeppey SY. Small diverse antioxidant functionalities for oxidative stress disease drug discovery. Mini Rev Med Chem. 2012 Jul; 12(8):768-74.
    View in: PubMed
    Score: 0.020
  9. Peprah K, Zhu XY, Eyunni SV, Setola V, Roth BL, Ablordeppey SY. Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents. Bioorg Med Chem. 2012 Feb 01; 20(3):1291-7.
    View in: PubMed
    Score: 0.019
  10. Sikazwe DM, Nkansah NT, Altundas R, Zhu XY, Roth BL, Setola V, Ablordeppey SY. Synthesis and evaluation of ligands for D2-like receptors: the role of common pharmacophoric groups. Bioorg Med Chem. 2009 Feb 15; 17(4):1716-23.
    View in: PubMed
    Score: 0.016
  11. Kumar EV, Etukala JR, Ablordeppey SY. Indolo[3,2-b]quinolines: synthesis, biological evaluation and structure activity-relationships. Mini Rev Med Chem. 2008 Jun; 8(6):538-54.
    View in: PubMed
    Score: 0.015
  12. Zhu XY, Mardenborough LG, Li S, Khan A, Zhang W, Fan P, Jacob M, Khan S, Walker L, Ablordeppey SY. Synthesis and evaluation of isosteres of N-methyl indolo[3,2-b]-quinoline (cryptolepine) as new antiinfective agents. Bioorg Med Chem. 2007 Jan 15; 15(2):686-95.
    View in: PubMed
    Score: 0.013
  13. Ablordeppey SY, Lyles-Eggleston M, Bricker B, Zhang W, Zhu X, Goodman C, Roth BL. Evaluation of the eutomer of 4-{3-(4-chlorophenyl)-3-hydroxypyrrolidin-1-yl}-1-(4-fluorophenyl)butan-1-one, {(+)-SYA 09}, a pyrrolidine analog of haloperidol. Bioorg Med Chem Lett. 2006 Jun 15; 16(12):3219-23.
    View in: PubMed
    Score: 0.013
  14. Lyles-Eggleston M, Altundas R, Xia J, Sikazwe DM, Fan P, Yang Q, Li S, Zhang W, Zhu X, Schmidt AW, Vanase-Frawley M, Shrihkande A, Villalobos A, Borne RF, Ablordeppey SY. Design, synthesis, and evaluation of metabolism-based analogues of haloperidol incapable of forming MPP+-like species. J Med Chem. 2004 Jan 29; 47(3):497-508.
    View in: PubMed
    Score: 0.011
  15. Sikazwe DM, Li S, Lyles-Eggleston M, Ablordeppey SY. The acute EPS of haloperidol may be unrelated to its metabolic transformation to BCPP+. Bioorg Med Chem Lett. 2003 Nov 03; 13(21):3779-82.
    View in: PubMed
    Score: 0.011
  16. Ablordeppey SY, Fischer JB, Law H, Glennon RA. Probing the proposed phenyl-A region of the sigma-1 receptor. Bioorg Med Chem. 2002 Aug; 10(8):2759-65.
    View in: PubMed
    Score: 0.010
  17. Ablordeppey SY, Fan P, Ablordeppey JH, Mardenborough L. Systemic antifungal agents against AIDS-related opportunistic infections: current status and emerging drugs in development. Curr Med Chem. 1999 Dec; 6(12):1151-95.
    View in: PubMed
    Score: 0.008
  18. Aguilar BJ, Nkembo AT, Duverna R, Poku RA, Amissah F, Ablordeppey SY, Lamango NS. Polyisoprenylated methylated protein methyl esterase: a putative biomarker and therapeutic target for pancreatic cancer. Eur J Med Chem. 2014 Jun 23; 81:323-33.
    View in: PubMed
    Score: 0.006
  19. Duverna R, Ablordeppey SY, Lamango NS. Biochemical and docking analysis of substrate interactions with polyisoprenylated methylated protein methyl esterase. Curr Cancer Drug Targets. 2010 Sep; 10(6):634-48.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support